Abstract
Peptide YY (PYY)3-36, released by intestinal lipid elicits functional effects that comprise the intestinal feedback response to luminal nutrients, but the pathway of action is not fully characterized. The aim of the present study was to determine the role of the apolipoprotein (apo) A-IV-cholecystokinin (CCK)1 receptor (CCK1R) pathway in exogenous PYY3-36-induced activation of the gut-brain axis and inhibition of gastric emptying and food intake. PYY3-36 (5 μg/100 g ip) significantly inhibited gastric emptying of a chow meal in wild-type but not A-IV-/- mice andCCK1R receptor blockade with devazepide (10 μg/100 g), abolished PYY3-36-induced inhibition of gastric emptying. PYY3-36-induced inhibition of food intake in both ad libitum-fed and 16-h fasted mice was unaltered in A-IV-/- mice, compared with wild-type controls, or by CCK1R receptor blockade with devazepide. PYY3-36 activated neurons in the midregion of the nucleus of the solitary tract (bregma -7.32 to -7.76 mm) in A-IV+/+ mice; this was measured by immunohistochemical localization of Fos protein. PYY 3-36-induced Fos expression was significantly reduced by 65% in A-IV+/+ mice pretreated systemically with the sensory neurotoxin capsaicin (5 mg/100 g), 78% by the CCK1R antagonist, devazepide (10 μg/100 g), and 39% by the Y2R antagonist, BIIE0246 (200 and 600 μg/100 g) and decreased by 67% in apo A-IV-/- mice, compared with A-IV +/+ controls. The data suggest a role for apo A-IV and the CCK 1Rin PYY3-36-induced activation of the vagal afferent pathway and inhibition of gastric emptying, but this is likely not the pathway mediating the effects of PYY3-36 on food intake.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4695-4703 |
| Number of pages | 9 |
| Journal | Endocrinology |
| Volume | 148 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2007 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Involvement of apolipoprotein A-IV and cholecystokinin1 receptors in exogenous peptide YY3-36-induced stimulation of intestinal feedback. / Whited, K. L.; Tso, P.; Raybould, Helen E.
In: Endocrinology, Vol. 148, No. 10, 10.2007, p. 4695-4703.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Involvement of apolipoprotein A-IV and cholecystokinin1 receptors in exogenous peptide YY3-36-induced stimulation of intestinal feedback
AU - Whited, K. L.
AU - Tso, P.
AU - Raybould, Helen E
PY - 2007/10
Y1 - 2007/10
N2 - Peptide YY (PYY)3-36, released by intestinal lipid elicits functional effects that comprise the intestinal feedback response to luminal nutrients, but the pathway of action is not fully characterized. The aim of the present study was to determine the role of the apolipoprotein (apo) A-IV-cholecystokinin (CCK)1 receptor (CCK1R) pathway in exogenous PYY3-36-induced activation of the gut-brain axis and inhibition of gastric emptying and food intake. PYY3-36 (5 μg/100 g ip) significantly inhibited gastric emptying of a chow meal in wild-type but not A-IV-/- mice andCCK1R receptor blockade with devazepide (10 μg/100 g), abolished PYY3-36-induced inhibition of gastric emptying. PYY3-36-induced inhibition of food intake in both ad libitum-fed and 16-h fasted mice was unaltered in A-IV-/- mice, compared with wild-type controls, or by CCK1R receptor blockade with devazepide. PYY3-36 activated neurons in the midregion of the nucleus of the solitary tract (bregma -7.32 to -7.76 mm) in A-IV+/+ mice; this was measured by immunohistochemical localization of Fos protein. PYY 3-36-induced Fos expression was significantly reduced by 65% in A-IV+/+ mice pretreated systemically with the sensory neurotoxin capsaicin (5 mg/100 g), 78% by the CCK1R antagonist, devazepide (10 μg/100 g), and 39% by the Y2R antagonist, BIIE0246 (200 and 600 μg/100 g) and decreased by 67% in apo A-IV-/- mice, compared with A-IV +/+ controls. The data suggest a role for apo A-IV and the CCK 1Rin PYY3-36-induced activation of the vagal afferent pathway and inhibition of gastric emptying, but this is likely not the pathway mediating the effects of PYY3-36 on food intake.
AB - Peptide YY (PYY)3-36, released by intestinal lipid elicits functional effects that comprise the intestinal feedback response to luminal nutrients, but the pathway of action is not fully characterized. The aim of the present study was to determine the role of the apolipoprotein (apo) A-IV-cholecystokinin (CCK)1 receptor (CCK1R) pathway in exogenous PYY3-36-induced activation of the gut-brain axis and inhibition of gastric emptying and food intake. PYY3-36 (5 μg/100 g ip) significantly inhibited gastric emptying of a chow meal in wild-type but not A-IV-/- mice andCCK1R receptor blockade with devazepide (10 μg/100 g), abolished PYY3-36-induced inhibition of gastric emptying. PYY3-36-induced inhibition of food intake in both ad libitum-fed and 16-h fasted mice was unaltered in A-IV-/- mice, compared with wild-type controls, or by CCK1R receptor blockade with devazepide. PYY3-36 activated neurons in the midregion of the nucleus of the solitary tract (bregma -7.32 to -7.76 mm) in A-IV+/+ mice; this was measured by immunohistochemical localization of Fos protein. PYY 3-36-induced Fos expression was significantly reduced by 65% in A-IV+/+ mice pretreated systemically with the sensory neurotoxin capsaicin (5 mg/100 g), 78% by the CCK1R antagonist, devazepide (10 μg/100 g), and 39% by the Y2R antagonist, BIIE0246 (200 and 600 μg/100 g) and decreased by 67% in apo A-IV-/- mice, compared with A-IV +/+ controls. The data suggest a role for apo A-IV and the CCK 1Rin PYY3-36-induced activation of the vagal afferent pathway and inhibition of gastric emptying, but this is likely not the pathway mediating the effects of PYY3-36 on food intake.
UR - http://www.scopus.com/inward/record.url?scp=34748844479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748844479&partnerID=8YFLogxK
U2 - 10.1210/en.2006-1665
DO - 10.1210/en.2006-1665
M3 - Article
C2 - 17641001
AN - SCOPUS:34748844479
VL - 148
SP - 4695
EP - 4703
JO - Endocrinology
JF - Endocrinology
SN - 0013-7227
IS - 10
ER -